Drugs and Devices

Drug approval for breast cancer

The U.S. Food and Drug Administration has approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.


Related Articles:

Leave a Reply

Your email address will not be published. Required fields are marked *

 

Shares